Lipocine (LPCN)CEO bought ~$51K

~$51K

Approx. value · 25K sh @ $2.03

161K

Holds after · shares reported

Traded

Apr 6, 2026

Filed

Apr 6, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Feb 18, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors (and 1 more item)
2. Mar 10, 2026Company filing · Form 8-K · ResultsReported its results
3. Apr 2, 2026Insider · 14 days before an 8-KCEO purchased ~$51K of LPCN shares in the open market
4. Apr 6, 2026 · this disclosureInsider · 10 days before an 8-KCEO purchased ~$51K of LPCN shares in the open market

What came next

1. Apr 6, 2026Insider · Largest insider buy since 2014Director purchased ~$252K of LPCN shares in the open market
2. Apr 7, 2026Insider · 9 days before an 8-KDirector purchased ~$81K of LPCN shares in the open market
3. Apr 16, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 16, 2026, Spyros Papapetropoulos informed the Board of Directors (the “Board”) of Lipocine Inc. (the “Company”) that he resigned as a member of the Board effective immediately.”
4. May 7, 2026Company filing · Form 8-K · ResultsReported its results
5. Jun 3, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers As noted below, on June 3, 2026, the shareholders of Lipocine Inc. (the “Company”) approved the Sixth Amended and Restated 2014 Stock and Incentive Plan (the “2014 Plan”).”
6. Aug 3, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On August 3, 2026, the Board of Directors of the Company expanded the Board of Directors to five members and appointed Michael Grissinger as a director, effective immediately.”
7. Aug 4, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Lipocine

For Lipocine, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LPCN page.

Other recent filings by Mahesh V. Patel, Chief Executive Officer

• SEC Form 4 at Lipocine (LPCN)Apr 2, 2026

The full history of Mahesh V. Patel, Chief Executive Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Lipocine

• SEC Form 4Oct 2, 2026
• SEC Form 4Oct 2, 2026
• SEC Form 4Oct 1, 2026
• SEC Form 4Apr 7, 2026
• SEC Form 4Apr 6, 2026
• SEC Form 4Apr 2, 2026

Everything OQRO holds on this company is on its LPCN page.